Inventiva S.A.

What they do

Inventiva is a biopharmaceutical company that develops small molecule therapies, primarily lanifibranor, a pan-PPAR agonist for metabolic and fatty liver diseases. The company is conducting clinical trials including a Phase II trial evaluating lanifibranor in combination with empagliflozin in patients with MASH/NASH and type 2 diabetes. It has out-licensed rights to lanifibranor in China, Hong Kong, Macau, and Taiwan to CTTQ through a licensing and collaboration agreement, and in Japan and South Korea to Hepalys. The company operates with a focus on clinical development and regulatory milestones.

Revenue drivers

• Licensing agreements and collaborations — The company has licensed lanifibranor rights to CTTQ in China and Hepalys in Japan and South Korea, receiving upfront payments, milestone payments, and royalties. These agreements are the primary source of reported revenue.
• Research and development milestones — The company may receive payments upon achieving specific clinical and regulatory milestones under its licensing agreements, such as successful trial results or regulatory approvals.
• Royalties on future sales — If licensed products are commercialized, the company is entitled to tiered royalties on net sales in the licensed territories.

Recent performance

In FY2025, total revenue was $1.1 million (all from licensing and collaboration agreements), down from $10.5 million in FY2024. The decrease was primarily due to the non-recurrence of upfront payments from the CTTQ and Hepalys agreements received in 2024. Operating expenses remained high, with R&D costs of $71.4 million and SG&A of $22.3 million, leading to a net loss of $119.5 million for the year. Cash and cash equivalents were $109.5 million at year-end.

Strategy

Management's strategy is to focus on advancing lanifibranor through clinical development, particularly the Phase IIb/III NATiV3 trial in MASH, and to leverage partnerships to expand into Asian markets. The company is also evaluating lanifibranor's potential in type 2 diabetes and other metabolic conditions. To fund operations, Inventiva has used various financing arrangements, including private placements, warrant agreements, and an at-market offering program. Additionally, it entered into a royalty certificate agreement to receive near-term cash in exchange for a portion of future US sales royalties from lanifibranor.

Risks

• Clinical trial failure — Lanifibranor is still in late-stage clinical trials, and failure to demonstrate efficacy or safety could prevent regulatory approval and severely harm the company.
• Dependence on partnerships — A large portion of future revenue depends on licensing partners like CTTQ and Hepalys achieving milestones and commercializing products, over which Inventiva has limited control.
• Financing risk — The company is not yet generating product revenue and relies on capital markets, which may not be accessible on favorable terms, leading to dilution or insufficient funding.
• Regulatory and competitive risk — The MASH/NASH space is highly competitive, and regulatory pathways are evolving; delays or changes in requirements could affect timelines and costs.

Outlook

Management expects to continue advancing the lanifibranor program, with data from the NATiV3 Phase III trial anticipated in the coming years. The company plans to use existing cash and financing facilities to fund operations into 2026. It may also seek additional partnerships or financing to extend runway beyond that point.